细胞治疗遗传性大疱性表皮松解症研究进展

doi:10.35541/cjd.20201116

Abstract

Abstract: 【Abstract】 Hereditary epidermolysis bullosa （EB） is a rare mutilating and lethal inherited single-gene skin disease, and places a heavy burden on society and families. Cell therapy has become a very promising method for the treatment of EB due to its excellent and stable clinical efficacy. This review summarizes progress in laboratory research and clinical application of stem cell- and somatic cell-based therapies in EB in recent years.

Key words: Epidermolysis bullosa, Tissue therapy, Stem cells, Tissue-engineered skin, Single-gene genodermatosis

Li Yue, Wu Jinyan, Yuan Ruoyue, Yang Quyang, Zhao Xiansheng, Zhu Ningwen. Cell therapy for hereditary epidermolysis bullosa[J]. Chinese Journal of Dermatology, 2023, 56(7): 698-702.doi:10.35541/cjd.20201116

References ［45］

［1］	Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility［J］. Br J Dermatol, 2020,183（4）:614⁃627. doi: 10.1111/bjd.18921.
［2］	Kocher T, Koller U. Advances in gene editing strategies for epidermolysis bullosa［J］. Prog Mol Biol Transl Sci, 2021,182:81⁃109. doi: 10.1016/bs.pmbts.2020.12.007.
［3］	Bonafont J, Mencía Á, García M, et al. Clinically relevant correction of recessive dystrophic epidermolysis bullosa by Dual sgRNA CRISPR/Cas9⁃mediated gene editing［J］. Mol Ther, 2019,27（5）:986⁃998. doi: 10.1016/j.ymthe.2019.03.007.
［4］	Hainzl S, Peking P, Kocher T, et al. COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa［J］. Mol Ther, 2017,25（11）:2573⁃2584. doi: 10.1016/j.ymthe.2017.07.005.
［5］	Izmiryan A, Ganier C, Bovolenta M, et al. Ex vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR/Cas9 and homology⁃directed repair［J］. Mol Ther Nucleic Acids, 2018,12:554⁃567. doi: 10.1016/j.omtn.2018.06. 008.
［6］	Jacków J, Guo Z, Hansen C, et al. CRISPR/Cas9⁃based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells［J］. Proc Natl Acad Sci U S A, 2019,116（52）:26846⁃26852. doi: 10.1073/pnas.190708 1116.
［7］	Takashima S, Shinkuma S, Fujita Y, et al. Efficient gene reframing therapy for recessive dystrophic epidermolysis bullosa with CRISPR/Cas9［J］. J Invest Dermatol, 2019,139（8）:1711⁃1721.e4. doi: 10.1016/j.jid.2019.02.015.
［8］	Eichstadt S, Barriga M, Ponakala A, et al. Phase 1/2a clinical trial of gene⁃corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa［J］. JCI Insight, 2019,4（19）:e130554. doi: 10.1172/jci.insight.130554.
［9］	Siprashvili Z, Nguyen NT, Gorell ES, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa［J］. JAMA, 2016,316（17）:1808⁃1817. doi: 10.1001/jama.2016. 15588.
［10］	Gaucher S, Lwin SM, Titeux M, et al. EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I/II gene therapy trial for recessive dystrophic epidermolysis bullosa［J］. Br J Dermatol, 2020,182（3）:794⁃797. doi: 10.1111/bjd.18559.
［11］	Bauer JW, Koller J, Murauer EM, et al. Closure of a large chronic wound through transplantation of gene⁃corrected epidermal stem cells［J］. J Invest Dermatol, 2017,137（3）:778⁃781. doi: 10.1016/j.jid.2016.10.038.
［12］	Prodinger C, Reichelt J, Bauer JW, et al. Epidermolysis bullosa: advances in research and treatment［J］. Exp Dermatol, 2019,28（10）:1176⁃1189. doi: 10.1111/exd.13979.
［13］	Lwin SM, Syed F, Di WL, et al. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa［J］. JCI Insight, 2019,4（11）:e126243. doi: 10.1172/jci.insight.126243.
［14］	Twaroski K, Eide C, Riddle MJ, et al. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa［J］. Br J Dermatol, 2019,181（6）:1247⁃1253. doi: 10.1111/bjd.17943.
［15］	Kowalewski C, Bremer J, Gostynski A, et al. Amelioration of junctional epidermolysis bullosa due to exon skipping［J］. Br J Dermatol, 2016,174（6）:1375⁃1379. doi: 10.1111/bjd.14374.
［16］	Bremer J, van der Heijden EH, Eichhorn DS, et al. Natural exon skipping sets the stage for exon skipping as therapy for dystrophic epidermolysis bullosa［J］. Mol Ther Nucleic Acids, 2019,18:465⁃475. doi: 10.1016/j.omtn.2019.09.009.
［17］	Turczynski S, Titeux M, Tonasso L, et al. Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in vivo RDEB model［J］. J Invest Dermatol, 2016,136（12）:2387⁃2395. doi: 10.1016/j.jid.2016.07.029.
［18］	Bremer J, Bornert O, Nyström A, et al. Antisense oligonucleotide⁃mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa［J］. Mol Ther Nucleic Acids, 2016,5（10）:e379. doi: 10.1038/mtna.2016.87.
［19］	Bornert O, Kühl T, Bremer J, et al. Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy［J］. Mol Ther, 2016,24（7）:1302⁃1311. doi: 10.1038/mt.2016.92.
［20］	South AP, Uitto J. Type VII Collagen Replacement therapy in recessive dystrophic epidermolysis bullosa⁃how much, how often?［J］. J Invest Dermatol, 2016,136（6）:1079⁃1081. doi: 10.1016/j.jid.2016.03.005.
［21］	Lincoln V, Cogan J, Hou Y, et al. Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa［J］. Proc Natl Acad Sci U S A, 2018,115（28）:E6536⁃E6545. doi: 10.1073/pnas.18031 54115.
［22］	Woodley DT, Cogan J, Hou Y, et al. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients［J］. J Clin Invest, 2017,127（8）:3028⁃3038. doi: 10.1172/JCI92707.
［23］	Atanasova VS, Jiang Q, Prisco M, et al. Amlexanox enhances premature termination codon read⁃through in COL7A1 and expression of full length type VII collagen: potential therapy for recessive dystrophic epidermolysis bullosa［J］. J Invest Dermatol, 2017,137（9）:1842⁃1849. doi: 10.1016/j.jid.2017.05.011.
［24］	Kwong A, Cogan J, Hou Y, et al. Gentamicin induces laminin 332 and improves wound healing in junctional epidermolysis bullosa patients with nonsense mutations［J］. Mol Ther, 2020,28（5）:1327⁃1338. doi: 10.1016/j.ymthe.2020.03.006.
［25］	Atanasova VS, Russell RJ, Webster TG, et al. Thrombospondin⁃1 is a major activator of TGF⁃β signaling in recessive dystrophic epidermolysis bullosa fibroblasts［J］. J Invest Dermatol, 2019,139（7）:1497⁃1505.e5. doi: 10.1016/j.jid.2019.01.011.
［26］	Schierling B, Dannemann N, Gabsalilow L, et al. A novel zinc⁃finger nuclease platform with a sequence⁃specific cleavage module［J］. Nucleic Acids Res, 2012,40（6）:2623⁃2638. doi: 10.1093/nar/gkr1112.
［27］	Chamorro C, Mencía A, Almarza D, et al. Gene editing for the efficient correction of a recurrent COL7A1 mutation in recessive dystrophic epidermolysis bullosa keratinocytes［J］. Mol Ther Nucleic Acids, 2016,5（4）:e307. doi: 10.1038/mtna.2016.19.
［28］	Supp DM, Hahn JM, Combs KA, et al. Collagen VII expression is required in both keratinocytes and fibroblasts for anchoring fibril formation in bilayer engineered skin substitutes［J］. Cell Transplant, 2019,28（9⁃10）:1242⁃1256. doi: 10.1177/0963689 719857657.
［29］	Lim YH, Fisher JM, Choate KA. Revertant mosaicism in genodermatoses［J］. Cell Mol Life Sci, 2017,74（12）:2229⁃2238. doi: 10.1007/s00018⁃017⁃2468⁃2.
［30］	Gostynski A, Deviaene FC, Pasmooij AM, et al. Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy［J］. Br J Dermatol, 2009,161（2）:444⁃447. doi: 10.1111/j.1365⁃2133.2009.09118.x.
［31］	Gostyński A, Pasmooij AM, Jonkman MF. Successful therapeutic transplantation of revertant skin in epidermolysis bullosa［J］. J Am Acad Dermatol, 2014,70（1）:98⁃101. doi: 10.1016/j.jaad. 2013.08.052.
［32］	Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells［J］. Nat Med, 2006,12（12）:1397⁃1402. doi: 10.1038/nm1504.
［33］	De Rosa L, Carulli S, Cocchiarella F, et al. Long⁃term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa［J］. Stem Cell Reports, 2013,2（1）:1⁃8. doi: 10.1016/j.stemcr.2013.11.001.
［34］	Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using transgenic stem cells［J］. Nature, 2017,551（7680）:327⁃332. doi: 10.1038/nature24487.
［35］	De Rosa L, Secone Seconetti A, De Santis G, et al. Laminin 332⁃dependent YAP dysregulation depletes epidermal stem cells in junctional epidermolysis bullosa［J］. Cell Rep, 2019,27（7）:2036⁃2049.e6. doi: 10.1016/j.celrep.2019.04.055.
［36］	Wu W, Lu Z, Li F, et al. Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model［J］. Proc Natl Acad Sci U S A, 2017,114（7）:1660⁃1665. doi: 10.1073/pnas.1614775114.
［37］	Itoh M, Kawagoe S, Tamai K, et al. Footprint⁃free gene mutation correction in induced pluripotent stem cell （iPSC） derived from recessive dystrophic epidermolysis bullosa （RDEB） using the CRISPR/Cas9 and piggyBac transposon system［J］. J Dermatol Sci, 2020,98（3）:163⁃172. doi: 10.1016/j.jdermsci.2020.04.004.
［38］	Wagner JE, Ishida⁃Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa［J］. N Engl J Med, 2010,363:629⁃39. doi: 10.1056/NEJMoa0910501.
［39］	Tolar J, Wagner JE. Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix［J］. Lancet, 2013,382（9899）:1214⁃1223. doi: 10.1016/S0140⁃6736（13）61897⁃8.
［40］	Ebens CL, McGrath JA, Tamai K, et al. Bone marrow transplant with post⁃transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts［J］. Br J Dermatol, 2019,181（6）:1238⁃1246. doi: 10.1111/bjd.17858.
［41］	Petrof G, Lwin SM, Martinez⁃Queipo M, et al. Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa［J］. J Invest Dermatol, 2015,135（9）:2319⁃2321. doi: 10.1038/jid.2015. 158.
［42］	Rashidghamat E, Kadiyirire T, Ayis S, et al. Phase I/II open⁃label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa［J］. J Am Acad Dermatol, 2020,83（2）:447⁃454. doi: 10.1016/j.jaad.2019.11.038.
［43］	Ebens CL, McGrath JA, Riedl JA, et al. Immune tolerance of allogeneic hematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds［J］. Br J Dermatol, 2021,184（6）:1161⁃1169. doi: 10.1111/bjd.19503.
［44］	Fujita Y, Komatsu M, Lee SE, et al. Intravenous injection of muse cells as a potential therapeutic approach for epidermolysis bullosa［J］. J Invest Dermatol, 2021,141（1）:198⁃202.e6. doi: 10. 1016/j.jid.2020.05.092.
［45］	Woodley DT, Cogan J, Wang X, et al. De novo anti⁃type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa［J］. J Invest Dermatol, 2014,134（4）:1138⁃1140. doi: 10.1038/jid.2013.475.

[1]	Wang Li, Ren Zengguo, Lou Guiyu, Zhang Yuwei, Yang Ke, Lei Xingxing, Zhang Bing, Liao Shixiu, Hao Bingtao. Genetic diagnosis in two families with dystrophic epidermolysis bullosa [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220061-e20220061.
[2]	Wang Junxia, Guo Weinan, Chen Hui, Hao Junfeng, Li Bing, Wei Jingyi, Zhao Tao. Efficacy of autologous fat grafting in the treatment of 40 cases of stable linear scleroderma: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 0(3): 20210866-e20210866.
[3]	Guo Weinan, Wang Junxia, Chen Hui, Hao Junfeng, Li Bing, Wei Jingyi, Zhao Tao. Clinical efficacy of autologous adipose-derived stem cell gel grafting in the treatment of depressed acne scars [J]. Chinese Journal of Dermatology, 2023, 0(3): 20210867-e20210867.
[4]	Wang Qi, Jian Zhe. Three-dimensional culture techniques of mesenchymal stem cells and their application in the treatment of skin diseases [J]. Chinese Journal of Dermatology, 2023, 0(2): 20230083-e20230083.
[5]	Ding Yuxin, Lyu Zhongfa. Stem cell therapy for alopecia areata [J]. Chinese Journal of Dermatology, 2022, 55(9): 835-838.
[6]	Yang Zhou, Xu Zhe, Wang Shan, Xu Jiaosheng, Han Xiaofeng, Ma Lin. Mutation analysis of the COL7A1 gene in 4 cases of recessive dystrophic epidermolysis bullosa [J]. Chinese Journal of Dermatology, 2022, 55(8): 653-658.
[7]	Chen Fuying, Yang Weiqin, Zhang Beibei, Wang Yumeng, Wang Jianbo, Yao Zhirong, Li Ming, . Rare subtypes of epidermolysis bullosa: three case reports and their pedigree analysis [J]. Chinese Journal of Dermatology, 2022, 55(8): 682-685.
[8]	Jin Liang, Liu Ling. Treatment of some genodermatoses [J]. Chinese Journal of Dermatology, 2022, 55(8): 735-739.
[9]	Bao Yingqiu, Zhang Yanjun, Li Bo, Gong Jing, Fu Yu, Xu Zhe. Gene therapy for recessive dystrophic epidermolysis bullosa [J]. Chinese Journal of Dermatology, 2022, 55(8): 739-743.
[10]	Zhang Shuchang, Ge Yicheng, Zhao Zhihao, Guo Pan, Xing Weibin, Hu Lizhi. Regulatory role of the transcriptional coactivator Mediator 1 in skin hair regeneration and its mechanisms [J]. Chinese Journal of Dermatology, 2022, 55(5): 401-407.
[11]	Xia Na, Gao Chao, Liu Xuan, Zou Dongxu, Ji Guangju, Cai Hong, . Role of umbilical cord mesenchymal stem cell-derived exosomes in acute skin wound healing [J]. Chinese Journal of Dermatology, 2022, 55(5): 382-388.
[12]	Wang Xiaoyu, Wang Wenhui, Dai Hui, Xie Jiawei, Wang Guanyu, Guo Jinzhu, Zhang Hua, Wang Xiujuan, Xu Yongsheng, Zhang Chunlei. Therapeutic effect of human umbilical cord mesenchymal stem cells on imiquimod?induced psoriasis-like mouse models [J]. Chinese Journal of Dermatology, 2021, 54(6): 485-492.
[13]	Wang Xiaopo, Chen Zhiming, Yang Yong, Sun Jianfang . A family of severe epidermolysis bullosa simplex caused by a de novo mutation in the KRT5 gene [J]. Chinese Journal of Dermatology, 2021, 54(3): 229-231.
[14]	Wang Xiaoyu, Zhang Chunlei, Wang Wenhui. Application of mesenchymal stem cells in psoriasis [J]. Chinese Journal of Dermatology, 2021, 54(11): 1019-1022.
[15]	Jin Xinxing, Li Sizhe, Zuo Yagang. Role of thymic stromal lymphopoietin in various skin diseases [J]. Chinese Journal of Dermatology, 2021, 54(10): 915-919.

Cell therapy for hereditary epidermolysis bullosa

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［45］

Related Articles 15

Metrics

Comments

Recommended 10